‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus

'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus.

BACKGROUND Intractable pruritus is a major problem for some patients with cholestasis. Albumin dialysis has been shown to ameliorate pruritus, but long-term outcome data are limited. AIM To evaluate the safety and efficacy of 'out-patient' albumin dialysis using the molecular adsorbent recirculating system (MARS) in the treatment of intractable pruritus in cholestatic patients referred for li...

Neuromediators for cholestatic pruritus

Cholestatic pruritus is one of the most common complaints in patients with liver diseases and intraor posthepatic cholestasis. The mechanisms of cholestatic pruritus remain poorly understood although multiple factors are considered to participate in the pathogenesis of cholestatic pruritus. Recent exciting studies have discovered several G-protein coupled receptors (GPCRs) and endogenous chemic...

Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.

BACKGROUND Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid ĸ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. MET...

Safety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease.

INTRODUCTION Cholestasis related pruritus, secondary to intrahepatic and/or extrahepatic biliary obstruction is a common manifestation in chronic liver disease. Pruritus is difficult to treat, and results are often suboptimal. A stepwise medical approach is usually employed, followed by a trial molecular adsorbents recirculation system in medication resistant cases. Pruritus resulting in reduce...

Pruritus responsive to naltrexone in a patient with cholestatic liver disease.